"Advanced therapies in Neurodegeneration: Bridging Neuroscience, Bioengineering and Optogenetics" Symposium
Due to COVID-19, the symposium had to be reorganized and will be held in the form of an online webinar on April 29 & 30, 2020. Registration is still open until the start of the event. The updated webinar program can be found here.
The Symposium on “Advanced therapies in Neurodegeneration: Bridging Neuroscience, Bioengineering and Optogenetics” is organized by the Early Stage Researchers of the Marie Skłodowska-Curie Actions Horizon 2020 project Training4CRM.
The event is free of charge, funded by Horizon 2020, and will feature a lot of interesting talks about Neuroscience, Neurodegenerative diseases like Parkinson's Disease, Huntington's Disease and Epilepsy, Stem Cell Therapy, Bioengineering and Optogenetics. More information about the symposium can be found here: http://training4crm.com/
Jenny Emnéus, Technical University of Denmark – European Network Training4CRM: Cell-based Regenerative Medicine for neurodegenerative diseases
Etienne Hirsch, ICM Paris – Why clinical trials fail in Parkinson disease
Ernest Arenas, Karolinska Institute – Cell replacement strategies for Parkinson’s disease: A single cell perspective.
Juan Jose Toledo Aral, IBiS Sevilla – Neuroprotective Carotid Body Cell therapy in Parkinson’s Disease
Selina Wray, University College London – Patient-derived stem cell models of Alzheimer's disease and frontotemporal dementia
Cláudia Cavadas, University of Coimbra – Role of hypothalamus in aging / Caloric restriction to block neurodegenerative disease
Anne Rosser, Cardiff University – Taking stem cells towards the clinic for Huntington's disease
Mercé Masana, University of Barcelona – Huntington’s disease & Optogenetics
My Andersson, Lund University – Epilepsy & Optogenetics
Nigel Hooper, University of Manchester – Reverse engineering a human blood-brain barrier platform for studying neurovascular disease
Maria Joana Albuquerque Osório, Center for Translational Neuromedicine, University of
Copenhagen – Cell and gene therapy for treatment of pediatric congenital disorders of myelin